Despite the significant efficacy of T-DM1 to target HER2+ breast cancer cells, most patients with HER2+ breast cancer treated with T-DM1 experience local recurrence or distant metastases after drug discontinuation. This evidence concerns the gene ERBB2 and breast carcinoma.